Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Janux Therapeutics, Inc.JANX · Entity 4864 | Chief Scientific Officer | January 02, 2026 | January 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Janux Therapeutics, Inc.
Report date January 02, 2026 · Filed January 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,425 |
Reported balance
After 2026-01-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-02 · Sale · Disposed 2,505 · Balance 124,425 F1: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2: Includes 4,049 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on May 15, 2025. Also, on January 3, 2025, the Reporting Person filed a Form 4 which inadvertently reported an aggregate of 7,781 shares acquired under the Plan. In fact, 5,432 of the shares were already reported as acquired by the Reporting Person under the Plan on a Form 3 filed on January 3, 2024 and 1,406 of the shares were reported as acquired by the Reporting Person under the Plan on a Form 4 filed on September 27, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 155,825 |
Reported balance
After 2026-01-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 31,400 · Balance 155,825 F3: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.65 · Expires 2036-01-01 | Direct | 109,900 |
Reported balance
After 2026-01-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-02 · Grant · Acquired 109,900 · Balance 109,900 F4: 25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F2: Includes 4,049 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on May 15, 2025. Also, on January 3, 2025, the Reporting Person filed a Form 4 which inadvertently reported an aggregate of 7,781 shares acquired under the Plan. In fact, 5,432 of the shares were already reported as acquired by the Reporting Person under the Plan on a Form 3 filed on January 3, 2024 and 1,406 of the shares were reported as acquired by the Reporting Person under the Plan on a Form 4 filed on September 27, 2024.
F3: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027.
F4: 25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 2, 2026 21:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock option (right to buy) · Derivative | 109,900 | $0.00 Strike: $13.65 | $0.00 |
DisclosureSEC source: 0002005618-26-000002 · form4-01022026_090110.xml · derivative · entry 3 DiRaimondo Thomas · CIK 0002005618 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,900 Underlying: Common Stock · 109,900 shares Expires 2036-01-01 F4 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2027 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 21:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 31,400 | $0.00 | $0.00 |
DisclosureSEC source: 0002005618-26-000002 · form4-01022026_090110.xml · nonDerivative · entry 2 DiRaimondo Thomas · CIK 0002005618 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,825 F3 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2027. Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 21:00 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 2,505 | $13.73 | $34,393.65 |
DisclosureSEC source: 0002005618-26-000002 · form4-01022026_090110.xml · nonDerivative · entry 1 DiRaimondo Thomas · CIK 0002005618 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,425 F1 · kind: The shares were automatically sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · balance_after: Includes 4,049 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on May 15, 2025. Also, on January 3, 2025, the Reporting Person filed a Form 4 which inadvertently reported an aggregate of 7,781 shares acquired under the Plan. In fact, 5,432 of the shares were already reported as acquired by the Reporting Person under the Plan on a Form 3 filed on January 3, 2024 and 1,406 of the shares were reported as acquired by the Reporting Person under the Plan on a Form 4 filed on September 27, 2024. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 20:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock option (right to buy) · Derivative | 84,000 | $0.00 Strike: $53.24 | $0.00 |
DisclosureSEC source: 0001415889-25-000673 · form4-01032025_080103.xml · derivative · entry 2 DiRaimondo Thomas · CIK 0002005618 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,000 Underlying: Common Stock · 84,000 shares Expires 2035-01-01 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 20:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000673 · form4-01032025_080103.xml · nonDerivative · entry 1 DiRaimondo Thomas · CIK 0002005618 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,719 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026. F2 · balance_after: Includes 497 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2021, 1,327 shares acquired under the Plan on May 13, 2022, 1,130 shares acquired under the Plan on November 15, 2022, 1,715 shares acquired under the Plan on May 15, 2023, 763 share acquired under the Plan on November 15, 2023, 1,406 shares acquired under the Plan on May 15, 2024 and 943 shares acquired under the Plan on November 15, 2024. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 19:31 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 675 | $47.22 | $31,876.54 |
DisclosureSEC source: 0001415889-24-024076 · form4-09272024_110948.xml · nonDerivative · entry 2 DiRaimondo Thomas · CIK 0002005618 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,938 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F4 · price: The weighted average sale price for the transaction reported was $47.2245 and the range of prices were between $46.79 and $47.77. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| September 27, 2024 Filed Sep 27, 2024 19:31 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 4,325 | $46.21 | $199,839.65 |
DisclosureSEC source: 0001415889-24-024076 · form4-09272024_110948.xml · nonDerivative · entry 1 DiRaimondo Thomas · CIK 0002005618 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,613 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024. F2 · price: The weighted average sale price for the transaction reported was $46.2057 and the range of prices were between $45.70 and $46.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · balance_after: Includes 1,406 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2024. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 16:47 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 147,000 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-24-000426 · doc4.xml · derivative · entry 1 DiRaimondo Thomas · CIK 0002005618 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,000 Underlying: Common Stock · 147,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.